ArticleThe Journal of infectious diseases2016
Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The expected impact of a cure for HIV among people with HIV and key populations.Communications medicine · 2025Article
- The long-term impact and value of curative therapy for HIV: a modelling analysis.Journal of the International AIDS Society · 2023Article
- Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity.Journal of virology · 2022Article
- Bringing Gene Therapies for HIV Disease to Resource-Limited Parts of the World.Human gene therapy · 2021Article
- Review
- Strengthening the scale-up and uptake of effective interventions for sex workers for population impact in Zimbabwe.Journal of the International AIDS Society · 2019Article
- The potential impact of a "curative intervention" for HIV: a modelling study.Global health research and policy · 2019Article
- Maximising the global health impact of future HIV cure-related interventions through advance planning.Journal of virus eradication · 2018Article
- Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?Journal of virology · 2017Article
- Barriers to HIV remission research in low- and middle-income countries.Journal of the International AIDS Society · 2017Review
- Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.Open forum infectious diseases · 2017Article
- The latest science from the IAS Towards an HIV Cure Symposium: 16-17 July 2016, Durban, South Africa.Journal of virus eradication · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundIt is unknown what properties would be required to make an intervention in low income countries that can eradicate or control human immunodeficiency virus (HIV) without antiretroviral therapy (ART) cost-effective.
methodsWe used a model of HIV and ART to investigate the effect of introducing an ART-free viral suppression intervention in 2022 using Zimbabwe as an example country. We assumed that the intervention (cost: $500) would be accessible for 90% of the population, be given to those receiving effective ART, have sufficient efficacy to allow ART interruption in 95%, with a rate of viral rebound of 5% per year in the first 3 months, and a 50% decline in rate with each successive year.
resultsAn ART-free viral suppression intervention with these properties would result in >0.53 million disability-adjusted-life-years averted over 2022-2042, with a reduction in HIV program costs of $300 million (8.7% saving). An intervention of this efficacy costing anything up to $1400 is likely to be cost-effective in this setting.
conclusionsInterventions aimed at curing HIV infection have the potential to improve overall disease burden and to reduce costs. Given the effectiveness and cost of ART, such interventions would have to be inexpensive and highly effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.